SCHEMBL3472479

SCHEMBL3472479

O=c1nc(-c2ccccc2)c2cc([N+](=O)[O-])ccc2n1Cc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 6/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ KMT2A Q03164 3/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ MAPT P10636 4/20 0.45
▸ HPGD P15428 2/20 0.45
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ PKM P14618 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CYP19A1 P11511 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11548824 0.89 L3MBTL1 (0.47) CFTRL3MBTL1KMT2AOPRK1MAPT
SCHEMBL3471111 0.86 L3MBTL1 (0.55) CFTRL3MBTL1KMT2AOPRK1ALOX5
SCHEMBL11550177 0.85 L3MBTL1 (0.52) CFTRL3MBTL1KMT2AOPRK1MAPT
SCHEMBL11604828 0.82 KMT2A (0.60) CFTRL3MBTL1KMT2AOPRK1MAPT
SCHEMBL11543948 0.82 POLB (0.49) CFTRMAPTPOLBLMNA
SCHEMBL11544946 0.82 L3MBTL1 (0.48) CFTRL3MBTL1KMT2AOPRK1CYP19A1
SCHEMBL11159597 0.81 L3MBTL1 (0.53) CFTRL3MBTL1KMT2AOPRK1MAPT
SCHEMBL11540068 0.81 L3MBTL1 (0.50) CFTRL3MBTL1KMT2AOPRK1MAPT
SCHEMBL11167732 0.81 MAPT (0.61) L3MBTL1KMT2AOPRK1MAPTHPGD
SCHEMBL11160397 0.81 L3MBTL1 (0.57) CFTRL3MBTL1KMT2AOPRK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2191832-A1 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2010-06-02 — — EP claimed
US-20040180912-A1 Quinazoline derivatives NOVARTIS AG (CH) 2004-09-16 — — US claimed
EP-1401451-A2 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2004-03-31 — — EP claimed
WO-2002102782-A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE NOVARTIS AG (CH) 2002-12-27 — — WO claimed
US-4146717-A NITROQUINAZOLINONE COMPOUNDS HAVING ANTIVIRAL PROPERTIES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-03-27 — — US claimed
US-8476286-B2 for promoting the release of parathyroid hormone, e.g. for preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable NOVARTIS AG (CH) 2013-07-02 — — US disclosed
EP-2191832-A1 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2010-06-02 — — EP disclosed
US-20040180912-A1 Quinazoline derivatives NOVARTIS AG (CH) 2004-09-16 — — US disclosed
EP-1401451-A2 QUINAZOLINE DERIVATIVES WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE Novartis AG (CH) 2004-03-31 — — EP disclosed
WO-2002102782-A2 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE NOVARTIS AG (CH) 2002-12-27 — — WO disclosed
US-4146717-A NITROQUINAZOLINONE COMPOUNDS HAVING ANTIVIRAL PROPERTIES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-03-27 — — US disclosed
US-3953446-A Process for preparing quinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1976-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180912-A1 Quinazoline derivatives PTH1R, PTMS, CALCA CFTR 2853/4885L3MBTL1 4552/4885KMT2A 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback